硫唑嘌呤与霉酚酸酯长期治疗肌炎相关间质性肺病
该回顾性研究纳入约翰霍普金斯医院接受硫唑嘌呤(AZA,66例)或霉酚酸酯(MMF,44例)且未联用其他保类固醇药物的肌炎相关间质性肺病(M-ILD)患者,采用线性混合效应模型(校正性别、年龄、抗合成酶抗体和吸烟状态)比较FVC%预计值、Dlco%预计值和泼尼松剂量的变化。两组FVC%预计值均改善且泼尼松剂量在2至5年内均下降;仅AZA组Dlco%预计值改善。校正模型显示两组治疗后FVC%预计值和Dlco%预计值无显著差异(平均差值分别为1.9和-8.2),但AZA组36个月时泼尼松剂量低6.6 mg。AZA组不良事件更频繁(33.3% vs 13.6%;P = .04)。
要点
- 在M-ILD患者中,AZA组和MMF组FVC%预计值均改善,泼尼松剂量在2至5年内均下降。
- 仅AZA组Dlco%预计值改善;校正模型显示两组治疗后FVC%预计值和Dlco%预计值无显著差异(平均差值1.9和-8.2)。
- AZA组36个月时泼尼松剂量较MMF组低6.6 mg。
- AZA组不良事件发生率高于MMF组(33.3% vs 13.6%;P = .04)。
- 治疗开始时AZA组平均FVC%预计值和Dlco%预计值均显著低于MMF组。
适用人群与场景
- 在约翰霍普金斯医院就诊并接受AZA或MMF治疗、未联用其他保类固醇药物的肌炎相关间质性肺病(M-ILD)患者。
研究设计与关键结果
- 回顾性研究纳入66例接受AZA和44例接受MMF的M-ILD患者;采用线性混合效应模型校正性别、年龄、抗合成酶抗体和吸烟状态。
- 治疗开始时AZA组平均FVC%预计值和Dlco%预计值显著低于MMF组。
- 两组FVC%预计值均改善且泼尼松剂量在2至5年内均下降;仅AZA组Dlco%预计值改善。
- 校正模型显示两组治疗后FVC%预计值和Dlco%预计值无显著差异(平均差值分别为1.9和-8.2),但AZA组36个月时泼尼松剂量低6.6 mg。
- AZA组不良事件更频繁(33.3% vs 13.6%;P = .04)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在M-ILD患者中,AZA治疗与FVC%预计值和Dlco%预计值改善及更低的泼尼松剂量相关;MMF治疗与FVC%预计值改善和泼尼松剂量降低相关。
- 治疗36个月后,接受AZA的患者泼尼松剂量低于接受MMF的患者。
- AZA组不良事件比MMF组更频繁(33.3% vs 13.6%;P = .04)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The efficacy of azathioprine (AZA) and mycophenolate mofetil (MMF) for interstitial lung disease (ILD) has been described, but mainly in connective tissue disease-associated ILD. The objective of this study was to evaluate the effect of AZA and MMF on lung function and prednisone dose in myositis-related ILD (M-ILD).
METHODS: In this retrospective study, patients with M-ILD seen at Johns Hopkins and treated with AZA or MMF and no other steroid-sparing agents were included. Linear mixed-effects models adjusted for sex, age, antisynthetase antibody, and smoking status were used to compare the change in FVC % predicted, diffusing capacity of the lungs for carbon monoxide (Dlco) % predicted, and prednisone dose.
RESULTS: Sixty-six patients with M-ILD were treated with AZA and 44 with MMF. At treatment initiation, mean FVC % predicted and Dlco % predicted were significantly lower in the AZA group than in the MMF group. In both groups, FVC % predicted improved and the prednisone dose was reduced over 2 to 5 years; however, for Dlco % predicted, only the AZA group improved. The adjusted model showed no significant difference in posttreatment FVC % predicted or Dlco % predicted between groups (mean difference of 1.9 and -8.2, respectively), but a 6.6-mg lower dose of prednisone at 36 months in the AZA group. Adverse events were more frequent with AZA than MMF (33.3% vs 13.6%; P = .04).
CONCLUSIONS: In M-ILD, AZA treatment was associated with improved FVC % predicted and Dlco % predicted, and lower prednisone dose. Patients treated with MMF had improved FVC % predicted and lower prednisone dose. After 36 months, patients treated with AZA received a lower prednisone dose than those treated with MMF.
参考来源
- Huapaya JA, Silhan L, Pinal-Fernandez I, et al. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. Chest. 2019. PMID: 31238042. doi:10.1016/j.chest.2019.05.023
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。